Hexagon Nutrition Listing: Premium of 7.22% on NSE & 6.67% on BSE

Key takeaways:
- Hexagon Nutrition Limited debuted at ₹48.25 on the NSE and at ₹48 on the BSE, respectively, at a premium of 7.22% and 6.67%.
- The public issue of ₹138.87 crore was oversubscribed by 53.68 times, with demand coming in from all investor categories.
- The company has a strong international footprint, with micronutrient premixes and therapeutic products being exported to over 75 countries.
- The company has shown strong financial performance in the pre-IPO period, with a total income of ₹331.29 crore and Profit After Tax (PAT) of ₹24.38 crore in FY25.
Hexagon Nutrition Limited, a leading research-driven holistic nutrition and wellness company, today made its debut on the Indian capital markets. The company officially went public by listing its equity shares on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE).
The IPO opened at a healthy premium of 7.22% on the NSE today at ₹48.25 per share and at a premium of 6.67% on the BSE at ₹48 per share, against the upper price band of ₹45 per share.
Here, we will delve into the Hexagon Nutrition IPO listing performance and its fundamentals.
Hexagon Nutrition Limited IPO Listing
Hexagon Nutrition's shares were officially listed on the Indian stock exchanges on June 12, 2026. The shares are listed at ₹48.25 on the NSE, at a healthy premium of 7.22%, while on the BSE, they got listed at ₹48, at a premium of 6.67% over the issue price. Following the listing, the shares have continued to trade with steady momentum, reflecting continued investor confidence.
Hexagon Nutrition Limited's positive listing of shares was in sync with its grey market premium (GMP) of ₹2.75 ahead of the listing day. Its attractive valuation, its established domestic market presence, and its high-margin export-oriented business model attracted a wide range of investors to its IPO, and were the reasons for the high subscription numbers and the positive lifting of the Hexagon Nutrition Limited IPO.
About Hexagon Nutrition Limited
Hexagon Nutrition Limited was incorporated in 1993 and is a premier research-oriented, pure-play nutrition company. The company has a variety of products, such as micronutrient premix formulations (B2B2C), branded wellness and clinical nutrition (B2C), therapeutic formulations, and ready-to-use foods (RUFs).
The company has three state-of-the-art manufacturing plants in India, one in Nasik (Maharashtra), one in Chennai, and one in Thoothukudi (Tamil Nadu), and an international manufacturing plant in Tashkent, Uzbekistan. Hexagon Nutrition has strategically placed its Special Economic Zone (SEZ) facilities in Chennai and Thoothukudi, which are close to the ports for efficient exports, as exports form a major part of its revenue.
Financially, the company has reported robust financials in its FY25 results. It reported a total income of ₹331.29 crore and Profit After Tax (PAT) of ₹24.38 crore in FY25.
Hexagon Nutrition Limited IPO Journey
The Hexagon Nutrition IPO subscription window opened on June 5, 2026 and closed on June 9, 2026. The company had offered shares in the price range of ₹42 to ₹45 per equity share with a minimum retail lot size of 333 shares. The issue was a 100% Offer for Sale (OFS) by the existing promoters and shareholders, and no fresh money was raised for future operations or expansion of the company.
The overall subscription for the IPO was 53.68 times. The retail segment had over subscribed its quota by 26.85 times and the NIIs category had over subscribed 161.49 times. QIBs rushed on the last day of bidding and subscribed to their quota by 19.77 times.
The company also raised ₹41.66 crore ahead of the public bidding process through over 92 lakh shares allotment to anchor investors, indicating high institutional confidence in the company's fundamentals.
Wrap up
The successful listing of Hexagon Nutrition Limited highlights the rising investor interest in the healthcare and clinical nutrition industry in India. The listing premium of approximately 7% reflects a steady debut of Hexagon Nutrition Limited. However, it is an attractive investment for long-term investors, given its strong export business, diversified B2B and B2C product portfolio, and consistent profitability.
The company's ability to sustain its high EBITDA margins, regulatory landscape, and growth in the clinical wellness segment will continue to be the key determinants of wealth creation in the long term as the company embarks on its journey as a publicly listed company.









